Profile Solutions, Inc. (PSIQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerProfile Solutions, Inc. (PSIQ) trades at $0.00005. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for PSIQ: PSIQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Profile Solutions, Inc. (PSIQ) Healthcare & Pipeline Overview
Profile Solutions, Inc. operates in the cannabinoid hemp extract market, offering edibles, creams, oils, and salves through its Elite Products International subsidiary. With a focus on both human and pet products, the company faces competition in the specialty and generic drug manufacturing sector, marked by a negative P/E ratio and volatile beta.
What Is the Investment Thesis for PSIQ?
Profile Solutions, Inc. presents a high-risk, high-reward investment profile within the cannabinoid hemp extract market. The company's negative P/E ratio of -0.08 and a profit margin of -58.4% indicate significant financial challenges. However, a gross margin of 55.3% suggests potential profitability if operational efficiencies are improved. Growth catalysts include expanding product lines and market reach within the burgeoning cannabinoid sector. The company's focus on both human and pet products diversifies its revenue streams. A key risk factor is the intense competition from larger, more established players like ABTI, BHCCF, CPHRF, EVGRF, and MAYNF. The company's OTC listing adds another layer of risk due to lower liquidity and disclosure requirements. Investors should closely monitor the company's ability to achieve profitability and navigate the regulatory landscape of the cannabinoid market.
Based on FMP financials and quantitative analysis
PSIQ Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -0.08 suggests the company is currently not profitable.
- Profit margin of -58.4% reflects significant operational challenges and high expenses.
- Gross margin of 55.3% indicates potential for profitability if operational efficiencies are improved.
- Beta of -10.33 suggests the stock price is highly volatile and inversely correlated with the market.
Who Are PSIQ's Competitors?
PSIQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BHCCF Benchmark Holdings plc | $0.37 | 0.00% | $225M | — |
| CPHRF Cipher Pharmaceuticals Inc. | $9.63 | +0.63% | $245M | — |
| MAYNF Mayne Pharma Group Limited | $2.00 | 0.00% | $162M | — |
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSIQ's Key Strengths?
Diversified product line including edibles, creams, oils, and salves.
- Focus on both human and pet cannabinoid products.
- Potential for high gross margins (55.3%).
What Are PSIQ's Weaknesses?
Negative P/E ratio and profit margin indicate financial instability.
- Small company size with only 5 employees.
- OTC listing suggests higher risk and lower liquidity.
What Are the Key Risks for PSIQ?
Intense competition from larger, more established players in the cannabinoid market.
- Evolving and uncertain regulatory landscape for cannabinoid products.
- Changes in consumer perception of cannabinoid products.
- The company's negative P/E ratio and profit margin indicate financial instability.
- OTC listing suggests higher risk and lower liquidity.
What Are PSIQ's Competitive Advantages?
- Focus on cannabinoid hemp extracts provides a niche market.
- Product diversification across edibles, creams, oils, and salves.
- Dual focus on human and pet products expands market reach.
What Does PSIQ Do?
Profile Solutions, Inc., headquartered in Sunrise, Florida, operates through its subsidiary, Elite Products International, Inc., focusing on the manufacturing and distribution of cannabinoid hemp extracts. The company's product line includes a variety of edibles like candies, gummies, cookies, crystal pops, honey, and multi-vitamins, as well as oils, tinctures, vapes, creams, and salves. They also offer specialized creams and salves designed for house pets, expanding their market reach within the wellness sector. The company's business model centers around providing cannabinoid-based products to consumers seeking alternative health and wellness solutions. While the company's history and founding details are not extensively documented, its current operations reflect a strategic focus on capitalizing on the growing demand for hemp-derived products. Profile Solutions navigates the competitive landscape of the specialty and generic drug manufacturing industry, emphasizing its cannabinoid offerings. Profile Solutions' geographic focus is primarily within the United States, leveraging its Florida headquarters for distribution and operations. The company's small size, with only 5 employees, suggests a lean operational structure, potentially allowing for agility in product development and market adaptation. However, this also presents challenges in scaling operations and competing with larger, more established players in the market.
What Products and Services Does PSIQ Offer?
- Manufactures cannabinoid hemp extracts.
- Distributes cannabinoid hemp extracts.
- Offers edibles such as candies, gummies, and cookies.
- Provides cannabinoid oils and tinctures.
- Produces cannabinoid creams and salves.
- Develops products for both human and pet use.
- Sells cannabinoid vapes.
How Does PSIQ Make Money?
- Manufacturing and selling cannabinoid hemp extracts through its subsidiary, Elite Products International, Inc.
- Generating revenue through the sale of edibles, creams, oils, salves, and vapes.
- Focusing on both direct-to-consumer sales and distribution through retail channels.
What Industry Does PSIQ Operate In?
Profile Solutions, Inc. operates within the rapidly evolving cannabinoid hemp extract market, a segment of the broader specialty and generic drug manufacturing industry. This market is characterized by increasing consumer demand for alternative wellness products and evolving regulatory landscapes. Competitors include companies like ABTI (American Biotechnology Corp), BHCCF (BevCanna Enterprises Inc), CPHRF (Captiva Verde Land Corp), EVGRF (Evergreen Sustainable Development), and MAYNF (MYM Nutraceuticals Inc), each vying for market share through product innovation and distribution strategies. The industry is subject to regulatory changes and consumer perception shifts, impacting growth and market dynamics.
Who Are PSIQ's Key Customers?
- Individuals seeking alternative health and wellness solutions.
- Pet owners looking for cannabinoid-based products for their animals.
- Retailers and distributors of cannabinoid products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Profile Solutions, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Sunrise, US. The company is led by CEO Dan Oran. PSIQ has traded publicly since 2007.
Key Financial Metrics
Return on assets is -89.8%, showing how much profit it generates from its asset base. A current ratio of 6.58 indicates the company holds enough short-term assets to cover its near-term obligations.
PSIQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PSIQ Latest News
No recent news available for PSIQ.
PSIQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PSIQ.
Price Targets
Wall Street price target analysis for PSIQ.
PSIQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PSIQ; grades run from A+ (80-100) to F (below 30).
Leadership: Dan Oran
Managing Director
Dan Oran serves as the managing director of Profile Solutions, Inc., overseeing the company's operations and strategic direction. His background includes experience in managing small teams and navigating the challenges of the cannabinoid hemp extract market. With a focus on product development and distribution, Oran is responsible for guiding the company's growth and ensuring regulatory compliance. His leadership is crucial for steering the company through the competitive landscape.
Track Record: Under Dan Oran's leadership, Profile Solutions, Inc. has focused on expanding its product line and market reach within the cannabinoid hemp extract sector. Key milestones include the development of specialized creams and salves for house pets and the establishment of distribution channels for its products. Oran's strategic decisions have been instrumental in navigating the evolving regulatory environment and positioning the company for future growth.
PSIQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available to the public, and trading activity can be sporadic and illiquid. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other listing.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or suspension of trading.
- Lack of regulatory oversight compared to listed exchanges.
- Verify the company's legal status and registration.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company manufactures and distributes cannabinoid hemp extracts.
- Products include edibles, creams, oils, and salves.
- Focus on both human and pet cannabinoid products.
Profile Solutions, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about PSIQ stock?
There is currently no available analyst coverage for PSIQ stock, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio, suggest the company is not currently profitable.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of analyst coverage.
- Financial data may not be fully up-to-date.